# GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

> **NCT00521014** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** rituximab
- **BIOLOGICAL:** sargramostim
- **DRUG:** carmustine
- **DRUG:** cytarabine
- **DRUG:** etoposide
- **DRUG:** melphalan
- **PROCEDURE:** autologous hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00521014
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2015-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00521014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00521014, "GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00521014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*